抗癌 化學療法을 施行한 末期 胃癌患者 에 對한 抗癌調理方과 AC 2 시럽의 效果에 關한 臨床的 考察

방대건,최서영 대한한방성인병학회 2000 韓方成人病學會誌 Vol.6 No.1

Objectives : This study was performed to evaluate the efficiency of Hangamjori-bang and ACⅡsyrup on the decrease side effects of chemotherapy in Stomach cancer patients. Methods : From September 1999 to June 2000, 9 stomach cancer patients were treated with chemotherapy in other hospital and treated with herb medicine (Hangamjori-bang and AC Ⅱsyrup) in Hana Oriental Hospital. Symptoms of patients were evaluated by symptom numeral scale at ① before chemotherapy ② during chemotherapy ③ treated by Herb medicine for 2 weeks after chemotherapy, and Blood analysis were performed. Results : After chemotherapy, Symptom numeral scale were significantly increased on the nausea/ vomitting and Total point compared to before chemotherapy. After Herb medicine (Hangamjori-bang and AC Ⅱsyrup) treated, symptom numeral scale was significantly decreased on the nausea/vomitting, indigestion, abdominal pain and total point compared to after chemotherapy. After herb medicine treatment, symptom numeral scale was significantly decreased on the abdominal pain compared to before chemotherapy and after chemotherapy. The changes of tumor marker (CA 72-4 and CEA) was not significant between before chemotherapy and chemotherapy + herb medcine combine treatment. In blool analysis blood, liver and kidney toxicity caused by western-oriental combine treatment were not seen. Conclusions : This result revealed that Hangamjori-bang and AC Ⅱsyrup were useful to decrease side effects of chemotherapy and symptoms of stomach cancer patients.

消癌去痰益機湯의 免疫調節作用과 細胞間交通에 對한 硏究

방대건,김진성,윤상협,류봉하,류기원 대한한방내과학회 2002 大韓韓方內科學會誌 Vol.23 No.4

시험관내 폐암(肺癌), 위암(胃癌) 및 신경교종(神經膠腫) 세포(細胞)에 대한 석웅황(石雄黃)의 항암효과(抗癌效果)

방대건,김진성,류봉하,Bang, Dae-Geon,Kim, Jin-Sung,Ryu, Bong-Ha 대한한방내과학회 2007 大韓韓方內科學會誌 Vol.28 No.2

Objectives : We are aimed to identify anti-tumor effects of realgar on some kinds of cancer cells through molecular biologic methods. Materials & Methods : We used 5 kinds of cancer cell lines: lung cancer cells(A549). stomach cancer cells(KATO) and neuroglioma cells(SUN-1118. U-87MG, U-373MG). We injected the boiled extracts of realgar $50{\mu}g$. $100{\mu}g$ to cultural media( ml )for 24 hours. We measured the killing effects on 5 kinds of cancer cells through inverted and fluorescence microscope, the suppressive effects on viability of those cells via XTT assay and the effects on the revelation of Bax and Bcl-2 proteins related to apoptosis by western blotting. Results : In the changes of morphology, the extracts of realgar showed more significant killing effects on all cancer cells. especially KATO, SNU-1118, U-87MG, U-373MG, than the control group with dose dependence, which was statistically significant. In XTT assay, the extracts of realgar showed more suppressive effects on viability of all cancer cells, especially KATO and U-373MG, than the control group with dose dependence, which was statistically significant. In the revelation of proteins related to apoptosis, the extracts of realgar increased the level of Bax and decreased that of Bcl-2 in all cancer cells with dose dependence. Conclusions : We identified that realgar had more anti-tumor effects on stomach cancer and neuroglioma than on lung cancer in the experiments above. However, these basic experiments were performed in vitro. We hope the anti-tumor effects of realgar will be practically identified through more progressive research.

膵臟轉移를 同伴한 原發性 肝癌 患者의 韓方 治療1例

방대건,최서영 대한한방성인병학회 2000 韓方成人病學會誌 Vol.6 No.1

We have experienced a case of Grade 4 Hepatocellular Carcinoma with metastasis to Pancreas treated by Oriental medical treatment - Herb medication, Acupuncture therapy, Herb and Coffee Retention Enema - and We have a meaningful result from that case to report it. After Diagnosis, this patient survived for 19 months while treated by oriental medical treatment. Symptoms of him most improved during 17 months and the tumor size and shape has not changed. At the last 2 months, symptoms has aggravated and metastasis has accured to the bone and he expired. According to this case, herbal treatment has a meaningful effect to the patient of terminal stage of liver cancer: improve the quality of life and general condition and prolong the duration of survival.

위암 및 간암환자의 치료에 있어 양.한방 협진의 효과에 관한 임상시험

이종인,심광용,김호영,최서영,방대건,조경숙,Lee, Chong-In,Shim, Kwang-Yong,Kim, Ho-Young,Choi, Seo-Young,Bang, Dae-Geon,Cho, Kyung-Sook 대한암한의학회 2001 大韓癌韓醫學會誌 Vol.7 No.1

Objectives: We compared the therapeutic response, the treatment-related toxicity, and the improvement of subjective symptoms between the chemotherapy alone group and the western-oriental combined treatment group and evaluated the role of oriental medicine for the improvement of chemotherapy-related toxicity in the advanced gastric cancer and hepatocellular carcinoma. Methods: We evaluated 36 gastric cancer or hepatocellular carcinoma patients(chemotherapy alone group 25 patients, combined treatment group 11 patients) who had been treated in Wonju Christian Hospital and Hana Hospital of Oriental Medicine between June 1999 and October 2000. Enrolled patients' general medical records, results of laboratory and imaging studies, treatment-related toxicities, and subjective symptoms were recorded regularly according to the planned protocol. Therapeutic responses were estimated according to the WHO response criteria and the changes of tumor marker value such as CEA, CA 72-4 and AFP. Results: 1. There was no significant difference of therapeutic response by the WHO response criteria between the two groups(p=.459). 2. There was a significant decrease of tumor marker value in the combined treatment group compared to the chemotherapy alone group(p=.023). 3. There was less comprehensive treatment-related toxicity in the combined treatment group compared to the chemotherapy alone group(p=.037), but there was not a significant difference of comprehensive improvement of subjective symptoms between the two groups(p=.091). Conclusions: Based on the above results, we could expect the possibility of improvements in therapeutic response and treatment-related toxicity with the western-oriental combined anticancer treatment.

VEGA의 FACTOR AA 중 구역 1, 2, 3에서의 두부 질환에 대한 연구

국윤형,민재영,오상덕,임승만,백은탄,이재혁,방대건,라수연 대한한방성인병학회 2000 韓方成人病學會誌 Vol.6 No.1

Objective : This study was to investigate the patterns among the normal people, the patients with non-brain diseases, such as headache, dizziness, Tou-feng(頭風), Feng-tou-xuan(風頭旋), etc and the patients with brain diseases, analysing the lead 1, 2, 3 of AA, FACTOR in VEGA. Methods : We analysed perspectively the lead 1, 2, 3 of AA, FACTOR in VEGA of 84 patients who undertook the VEGA during July and August, 2000. We evaluated the VEGA results by using Mann-Whitney U test. Results : This study showed that the mean of the patients with non-brain diseases was the highest, and the mean of the patients with brain diseases was the lowest, but there was no particular significance, when using the test. Conclusion : The chief point was that VEGA has no meaning in determining the difference among the normal people, the patients with headache, dizziness, Tou-feng, Feng-tou-xuan, etc and the ones with brain diseases.

진행성 위암 및 간암에서 양한방 협진의 치료효과

김호영,이종인,심광용,윤상진,박종구,방대건,최서영,이창훈 건국대학교 의과학연구소 2004 건국의과학학술지 Vol.13 No.-

Objectives: We compared the therapeutic response, the treatment-related toxicity, and the improvement of subjective symptoms between the chemotherapy alone group and the western-oriental combined treatment group and evaluated the role of oriental medicine for the improvement of chemotherapy-related toxicity in gastric cancer and hepatocellular carcinoma. Methods: We evaluated 36 gastric cancer or hepatocellular carcinoma patients(chemotherapy alone group 25 patients, combined treatment group 11 patients) who had been treated in Wonju Christian Hospital and Hana Hospital of Oriental Medicine between June 1999 and October 2000. Enrolled patients' general medical records, results of laboratory and imaging studies, treatment-related toxicities, and subjective symptoms were recorded regularly according to the planned protocol. Therapeutic responses were estimated according to the WHO response criteria and the changes of tumor marker such as CEA, CA 72-4 and AFP. Results: 1. There was no significant difference of therapeutic response by the WHO response criteria 2. There was a significant decrease of tumor marker results in the combined treatment group compared to the chemotherapy alone group(p=.023). 3. There was less comprehensive treatment-related toxicity in the combined treatment group compared to the chemotherapy alone group(p=.037), but there was no significant difference of comprehensive improvement of subjective symptoms between the two groups(p=.091). Conclusions: Based on the above results, we could expect the possibility of improvements in therapeutic response and treatment-related toxicity with the western-oriental combined anticancer treatment. between the two groups(p=.459).